Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-07-15
2008-07-15
Andres, Janet L. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S247000, C514S253030, C514S339000
Reexamination Certificate
active
07399762
ABSTRACT:
Structurally novel opioid receptor agonists are provided, and the use of these agonists in treatment of chronic and/or acute pain.
REFERENCES:
patent: 4529736 (1985-07-01), McKenzie et al.
patent: 5128118 (1992-07-01), Carroll et al.
patent: 5141959 (1992-08-01), Carroll et al.
patent: 5298499 (1994-03-01), Carroll et al.
patent: 5380848 (1995-01-01), Kuhar et al.
patent: 5413779 (1995-05-01), Kuhar et al.
patent: 5496953 (1996-03-01), Kuhar et al.
patent: 5736123 (1998-04-01), Carroll
patent: 5831095 (1998-11-01), Gonzalez et al.
patent: 5935953 (1999-08-01), Kuhar et al.
patent: 6123917 (2000-09-01), Carroll
patent: 6329520 (2001-12-01), Carroll et al.
patent: 6358492 (2002-03-01), Kuhar et al.
patent: 6416735 (2002-07-01), Carroll et al.
patent: 6479509 (2002-11-01), Carroll
patent: 6531481 (2003-03-01), Carroll et al.
patent: 6531483 (2003-03-01), Kuhar et al.
patent: 6538010 (2003-03-01), Carroll
patent: 6552032 (2003-04-01), Carroll et al.
patent: 6559159 (2003-05-01), Carroll et al.
patent: 6593348 (2003-07-01), Carroll et al.
patent: 6706880 (2004-03-01), Carroll et al.
patent: 6900228 (2005-05-01), Carroll et al.
patent: 2002/0132828 (2002-09-01), Carroll et al.
patent: 2002/0188003 (2002-12-01), Kuhar et al.
patent: 2003/0158415 (2003-08-01), Carroll et al.
patent: 2003/0176434 (2003-09-01), Carroll
patent: 2003/0203934 (2003-10-01), Kuhar et al.
patent: 2004/0146518 (2004-07-01), Carroll et al.
Peng et al, Journal of Medicinal Chemistry (2005), 48(5), 1620-1629.
Carroll et al,Journal of Medicinal Chemistry (2004), 47(2), 281-284.
Bertha et al, Journal of Medicinal Chemistry (1995), 38(9), 1523-37.
A.F. Abdel-Magid, et al., “Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride. Studies on Direct and Indirect Reductive Amination Procedures”, J. Org. Chem., 61, 1996, pp. 3849-3862.
J.V. Aldrich, et al., “Narcotic Analgesics”, Burger's Medicinal Chemistry and Drug Discover, vol. 6, Chapter 7, 2003, pp. 329-481.
D.S. Bruce, et al., “Circannual Variations in Bear Plasma Albumin and its Opioid-Like Effects on Guinea Pig Ileum”, Pharmacology Biochemistry and Behavior, vol. 53, No. 4, 1996, pp. 885-889.
Y. Chen, et al., “Molecular Cloning and Functional Expression of a μ-Opioid Receptor From Rat Brain”, Molecular Pharmacology, vol. 44, 1993, pp. 8-12.
A.D. Corbett, et al., “Dynorphin 1-8 and Dynorphin 1-9 are Ligands for the κ-Subtype of Opiate Receptor”, Nature, vol. 299, Sep. 2, 1982, pp. 79-81.
C.M. Bertha, et al., “Probes for Narcotic Receptor-Mediated Phenomena. 21. Novel Derivatives of 3-(1,2,3,4,5,11-Hexahydro-3-Methyl-2,6-Methano-6H-Azocino [4,5-b] indol-6-yl)-Phenols With Improved δ Opioid Receptor Selectivity”, J. Med. Chem., 39, 1996, pp. 2081-2086.
C.J. Evans, et al., “Cloning of a Delta Opioid Receptor by Functional Expression”, Science, vol. 258, Dec. 18, 1992, pp. 1952-1955.
X.-P. Gu, et al., “2-Chloro-1-(Chloromethyl)Ethyl Methoxymethyl Ether as a Reagent for Acetonylation of Alcohols and Phenol”, J. Org. Chem., 51, 1986, pp. 5425-5427.
X.-P. Gu, et al., “2-(Chloromethyl)-3,5-Dioxahex-1-Ene. An Effective Acetonylating Reagent”, J. Org. Chem., 52, 1987, pp. 3192-3196.
X.-P. Gu, et al, “Catalytic Acetonylation of Cyclic 1,3-Dicarbonyl-Systems by 2-(Chloromethyl)-3,5-Dioxa-1-Hexene”, Synthesis, 1988, pp. 535-537.
R.M. Jones, et al., “Mutational Evidence for a Common κ Antagonist Binding Pocket in the Wild-Type κ and Mutant μ [K303E] Opioid Receptors”, Journal of Medicinal Chemistry, vol. 41, No. 25, Dec. 3, 1998, pp. 4911-4914.
B.L. Kieffer, et al., “The δ-Opioid Receptor: Isolation of a CDNA by Expression Cloning and Pharmacological Characterization”, Proc. Natl. Acad. Sci, USA, vol. 89, Dec. 1992, pp. 12048-12052.
A. Marki, et al., “μ-Opioid Receptor Specific Antagonist Cyprodime: Characterization by in vitro Radioligand and [35S]GTPγS Binding Assays”, European Journal of Pharmacology, 383, 1999, pp. 209-214.
F. Meng, et al., “Cloning and Pharmacological Characterization of a Rat κ Opioid Receptor”, Proc. Natl. Acad. Sci. USA, vol. 90, Nov. 1993, pp. 9954-9958.
M. Minami, et al., “Cloning and Expression of a CDNA for the Rat κ-Opioid Receptor”, FEBS, vol. 329, No. 3, Aug. 1993, pp. 291-295.
M. Nishi, et al., “CDNA Cloning and Pharmacological Characterization of an Opioid Receptor With High Affinities for κ-Subtype-Selective Ligands”, FEBS, vol. 330, No. 1, Sep. 1993, pp. 77-80.
S.L. Olmsted, et al., “A Remarkable Change of Opioid Receptor Selectivity on the Attachment of a Peptidomimetic κ Address Element to the δ Antagonist, Natrindole: 5′-[N2-Alkylamidino)Methyl]Naltrindole Derivatives as a Novel Class of κ Opioid Receptor Antagonists”, J. Med. Chem., 36, 1993, pp. 179-180.
C.B. Pert, et al., “Opiate Receptor: Demonstration in Nervous Tissue”, Science, vol. 179, Mar. 9, 1973, pp. 1011-1014.
P.S. Portoghese, et al., “Binaltorphimine and Mor-Binaltorphimine, Potent and Selective κ-Opioid Receptor Antagonists”, Life Sciences, vol. 40, 1987, pp. 1287-1292.
P.S. Portoghese, “The Design of δ-Selective Opioid Receptor Antagonists”, II Farmaco, vol. 48, No. 2, 1993, pp. 243-251.
R. Schwyzer, “ACTH: A Short Introductory Review”, Annals New York Acad of Sciences, 1977, pp. 3-26.
P.L. Smiley , et al., “Effects of Cocaine on Extrapyramidal and Limbic Cynorphin Systems”, Journal of Pharmacology and Experimental Therapeutics, vol. 253, No. 3, 1990, pp. 938-943.
R. Spanagel, et al., “Modulation of Morphine-Induced Sensitization by Endogenous κ Opioid Systems in the Rat”, Neuroscience Letters, 153, 1993, pp. 232-236.
R. Spanagel, et al. “Opposing Tonically Active Endogenous Opioid Systems Modulate the Mesolimbic Dopaminergic Pathway”, Proc. Natl. Acad. Sci. USA, vol. 89, Mar. 1992, pp. 2046-2050.
J.B. Thomas, et al., “Investigation of the N-Substituent Conformation Governing Potency and μ Receptor Subtype-Selectivity in (+)-(3R,4R)-Dimethyl-4-—3-Hydroxyphenyl)-Piperidine Opioid Antagonists”, J. Med. Chem., 41, 1998, pp. 1980-1990.
J.B. Thomas, et al., “N-Substituted 9β-Methyl -5-(3-Hydroxyphenyl) Morphans are Opioid Receptor Pure Antagonists”, J. Med. Chem., 41, 1998, pp. 4143-4149.
J.B. Thomas, et al., “A Stereoselective Synthetic Approach to N-Alkyl-4β-Methyl-5-Phenylmorphans”, Tetrahedron Letters, 40, 1999, pp. 403-406.
R. C. Thompson, et al., “Cloning and Pharmacological Characterization of a Rat μ Opioid Receptor”, Neuron, vol. 11, Nov. 1993, pp. 903-913.
K.A. Trujillo, et al., “Changes in Prodynorphin Peptide Content Following Treatment With Morphine or Amphetamine: Possible Role in Mechanisms of Action of Drug of Abuse”, NIDA Res Mono, 95, 1989, pp. 550-551.
J.R. Volpicelli, et al., “Effect of Anltrexone on Alcohol “High” in Alcoholics”, Am. J. Pschiatry, 152, Apr. 1995, pp. 613-615.
J.R. Volpicelli, et al., “Naltrexone in the Treatment of Alcohol Dependence”, Arch Gen Psychiatry, vol. 49, Nov. 1992, pp. 876-880.
J.-B. Wang, et al., “Human β Opiate Receptor CDNA and Genomic Clones, Pharmacologic Characterization and Chromosomal Assignment”, FEBS Letters, 338, 1994, pp. 217-222.
J.A. Werner, et al., “Synthesis of Trans-3,4-Dimethyl -4-(3-Hydroxyphenyl) Piperidine Opioid Antagonists: Application of the CIS-Thermal Elimination of Carbonates to Alkaloid Synthesis”, J. Org. Chem., 61, 1996, pp. 587-597.
J.E. Zadina, et al., “A Potent and Selective Endogenous Agonist for the -Opiate Receptor”, Nature, vol. 386, Apr. 3, 1997, pp. 499-502.
D.M. Zimmerman, et al., “Synthesis and Analgesic Properties of N-Substitu
Carroll Frank Ivy
Navarro Hernan A.
Andres Janet L.
Covington Raymond
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
Research Triangle Institute
LandOfFree
Opioid receptor agonist compounds and their use in treatment... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Opioid receptor agonist compounds and their use in treatment..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Opioid receptor agonist compounds and their use in treatment... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2815565